

Supplementary Table S1. Search strategy in the PubMed and Embase

PubMed	Search strategy
#1	"Lipids/blood"[Mesh] OR "Triglycerides"[Mesh] OR "Cholesterol"[Mesh]
#2	"Triacylglycerol"[Title/Abstract] OR "Triacylglycerols"[Title/Abstract] OR "Epicolesterol"[Title/Abstract] OR "alpha Lipoprotein Cholesterol"[Title/Abstract] OR "Cholesterol alpha Lipoprotein"[Title/Abstract] OR "HDL Cholesterol"[Title/Abstract] OR "High Density Lipoprotein Cholesterol"[Title/Abstract] OR "Cholesterol HDL2"[Title/Abstract] OR "HDL2 Cholesterol"[Title/Abstract] OR "Cholesterol HDL3"[Title/Abstract] OR "HDL3 Cholesterol"[Title/Abstract] OR "Low Density Lipoprotein Cholesterol "[Title/Abstract] OR "beta Lipoprotein Cholesterol"[Title/Abstract] OR "Cholesterol beta Lipoprotein"[Title/Abstract] OR "LDL Cholesterol"[Title/Abstract] OR "Cholesteryl Linoleate LDL"[Title/Abstract] OR "LDL Cholesteryl Linoleate"[Title/Abstract] OR "lipids"[Title/Abstract] OR "serum lipid"[Title/Abstract] OR "Triglycerides"[Title/Abstract] OR "Triglyceride"[Title/Abstract] OR "Cholesterol"[Title/Abstract] OR "Total Cholesterol"[Title/Abstract] OR "TG"[Title/Abstract] OR "TC"[Title/Abstract] OR "HDL-C"[Title/Abstract] OR "LDL-C"[Title/Abstract]
#3	#1 OR #2
#4	"Colorectal Neoplasms"[Mesh]
#5	"Colorectal Neoplasms"[Title/Abstract] OR "Colorectal Neoplasm"[Title/Abstract] OR "Neoplasm Colorectal"[Title/Abstract] OR "Colorectal Carcinoma"[Title/Abstract] OR "Carcinoma Colorectal"[Title/Abstract] OR "Carcinomas Colorectal"[Title/Abstract] OR "Colorectal Carcinomas"[Title/Abstract] OR "Colorectal Cancer"[Title/Abstract] OR "Cancer Colorectal"[Title/Abstract] OR "Cancers Colorectal"[Title/Abstract] OR "Colorectal Cancers"[Title/Abstract] OR "Colorectal Tumors"[Title/Abstract] OR "Colorectal Tumor"[Title/Abstract] OR "Tumor Colorectal"[Title/Abstract] OR "Tumors Colorectal"[Title/Abstract] OR "Neoplasms Colorectal"[Title/Abstract] OR "CRC"[Title/Abstract]
#6	#4 OR #5
#7	#3 AND #6

Embase	Search strategy
#1	lipid blood level/exp OR lipids:ab,ti OR serum lipid:ab,ti OR Triacylglycerol/exp OR Triacylglycerol:ab,ti OR Triacylglycerols:ab,ti OR Triglycerides:ab,ti OR Triglyceride:ab,ti OR Cholesterol/exp OR Epicholesterol:ab,ti OR alpha Lipoprotein Cholesterol:ab,ti OR Cholesterol alpha Lipoprotein:ab,ti OR HDL Cholesterol:ab,ti OR High Density Lipoprotein Cholesterol:ab,ti OR Cholesterol HDL2:ab,ti OR HDL2 Cholesterol:ab,ti OR Cholesterol HDL3:ab,ti OR HDL3 Cholesterol:ab,ti OR Low Density Lipoprotein Cholesterol:ab,ti OR beta Lipoprotein Cholesterol:ab,ti OR Cholesterol beta Lipoprotein:ab, ti OR LDL Cholesterol:ab,ti OR Cholesteryl Linoleate LDL:ab,ti OR LDL Cholesteryl Linoleate:ab,ti OR Cholesterol:ab,ti OR Total Cholesterol:ab,ti OR TG:ab,ti OR TC:ab,ti OR HDL -C:ab,ti OR LDL -C:ab,ti
#2	colorectal tumor/exp OR Colorectal Neoplasms:ab,ti OR Colorectal Neoplasm:ab,ti OR Neoplasm Colorectal:ab,ti OR Colorectal Carcinoma:ab,ti OR Carcinoma Colorectal:ab,ti OR Carcinomas Colorectal:ab,ti OR Colorectal Carcinomas:ab,ti OR Colorectal Cancer:ab,ti OR Ca ncer Colorectal:ab,ti OR Cancers Colorectal:ab,ti OR Colorectal Cancers:ab,ti OR Colorectal Tumors:ab,ti OR Colorectal Tumor:ab,ti OR Tumor Colorectal:ab,ti OR Tumors Colorectal:ab,ti OR Neoplasms Colorectal:ab,ti OR CRC:ab,ti
#3	#1 AND #2

Supplementary Table S2. Characteristics of included prospective studies of serum lipids and colorectal cancer risk

First author, publication year (reference), Country, Type	Cases/subject year (reference), Country, (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Li et al[16]*, 2019, China, CS	394/104,333 (mean, 51.2y), 10y	Men: Triglycerides ≥ 1.7 vs. < 1.7 mmol/l (CRC) HDL cholesterol ≥ 1.03 vs. < 1.03 mmol/l (CRC)	1.12 (0.90–1.41) 0.81 (0.54–1.19)	Age, education level, income status, frequency of tobacco smoking, frequency of alcohol drinking, and sitting time
Katzke et al[17], 2017, Germany, C-CS	256/25,546 (35-65y), 18y	All: Triglycerides Q4 vs. Q1 (CRC) Total cholesterol Q4 vs. Q1 (CRC) HDL cholesterol Q4 vs. Q1 (CRC)	1.17 (0.74-1.84) 1.30 (0.84-2.01) 1.12 (0.73-1.73)	Age, sex, baseline height, waist, BMI, lifetime alcohol consumption, red meat intake, fibre intake, smoking status, socioeconomic status, physical activity, diabetes, hypertension and use of lipid lowering drugs
Muka et al[24], 2016, Netherlands, CS	248/6,628 (mean, 69.6y), 22y	All: Total cholesterol 262.55-694.98 vs. 84.94-239.38 mg/dl (CRC)	1.49 (1.08-2.06)	Age, sex, total energy intake, polyunsaturated fatty acids intake, Dutch Healthy Diet index excluding fish and polyunsaturated fatty acids component, processed red meat, unprocessed red meat, dietary fish intake, calcium intake, alcohol intake, physical activity, smoking status, BMI, waist-to-hip ratio, education level, income level, diabetes mellitus, family history of diabetes mellitus, family history of cardiovascular diseases, family history of cancer, history of gallbladder operations, anti-inflammatory and antirheumatic drugs, hormone replacement therapy, lipid lowering medication drugs

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Chandler et al[11], 2016, USA, CS	198/15,602 (≥45y), 21y	Women: Triglycerides Q4 vs. Q1 (CRC) Total cholesterol Q4 vs. Q1 (CRC) HDL cholesterol Q4 vs. Q1 (CRC) LDL cholesterol Q4 vs. Q1 (CRC)	1.86 (1.17-2.97) 1.21 (0.80-1.84) 0.63 (0.41-0.98) 1.14 (0.77-1.68)	Age, race, treatment random assignment, hormone replacement therapy, cigarette smoking, exercise, alcohol consumption, postmenopausal status, family history of cancer, aspirin use, history of colon polyps, total vegetable and fruit intake, history of mammogram, red meat intake and BMI
Lu et al[12]*, 2015, Norway, CS	2,044/143,477 (mean, 50.9y), 15y	All: Triglycerides ≥1.7 vs. <1.7 mmol/l (CRC) HDL cholesterol ≥1.03 (male) and ≥1.29 (women) vs. <1.03 (male) and <1.29 (women) mmol/l (CRC)	1.12 (1.02-1.22) 0.93 (0.85-1.03)	Age, sex, smoking, alcohol consumption, physical activity, education, family history of cancer, and BMI
Shin et al [25], 2014, Korea, CS	9,147/1,326,058 (30-80y), 11y	Men: Total cholesterol ≥240 vs. ≤200 mg/dl (CRC) Total cholesterol ≥240 vs. ≤200 mg/dl (CC) Total cholesterol ≥240 vs. ≤200 mg/dl (RC)	1.16 (1.08-1.26) 1.09 (0.97-1.23) 1.25 (1.12-1.40)	Age

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Agnoli et al [18], 2014, Italy, C-CS	286/850 (N/A), 15y	All: Triglycerides 138.84-1124.07 vs. 32.04-89.44 mg/dl (CRC) Total cholesterol 246.19-417.46 vs. 72.25-204.71 mg/dl (CRC) HDL cholesterol 68.54-129.02 vs. 24.19-55.10 mg/dl (CRC) LDL cholesterol 155.17-290.27 vs. 24.10-121.53 mg/dl (CRC) Men: Triglycerides 138.84-1124.07 vs. 32.04-89.44 mg/dl (CRC) Total cholesterol 246.19-417.46 vs. 72.25-204.71 mg/dl (CRC) HDL cholesterol 68.54-129.02 vs. 24.19-55.10 mg/dl (CRC) LDL cholesterol 155.17-290.27 vs. 24.10-121.53 mg/dl (CRC) Women: Triglycerides 138.84-1124.07 vs. 32.04-89.44 mg/dl (CRC) Total cholesterol 246.19-417.46 vs. 72.25-204.71 mg/dl (CRC) HDL cholesterol 68.54-129.02 vs. 24.19-55.10 mg/dl (CRC) LDL cholesterol 155.17-290.27 vs. 24.10-121.53 mg/dl (CRC)	1.32 (0.89-1.95) 1.66 (1.12-2.45) 0.85 (0.56-1.28) 1.87 (1.27-2.76) 1.77 (0.88-3.55) 2.54 (1.35-4.79) 0.69 (0.30-1.59) 2.90 (1.51-5.56) 1.12 (0.66-1.89) 1.41 (0.83-2.39) 0.87 (0.52-1.47) 1.65 (0.97-2.78)	Age, gender, BMI, smoking, total physical activity, alcohol consumption, dietary red meat, dietary fiber, and dietary calcium, and menopause status (for women); stratified by center
Strohmaier et al [37], 2013, European, CS	4,935/577,330 (mean, 44y), 11.7y	Men: Total cholesterol Q5 vs. Q1 (CC) Total cholesterol Q5 vs. Q1 (RC) Women: Total cholesterol Q5 vs. Q1 (CC) Total cholesterol Q5 vs. Q1 (RC)	1.18 (0.92-1.51) 1.09 (0.81-1.48) 1.23 (0.90-1.69) 1.48 (0.94-2.32)	Age, BMI, smoking status, and stratified by cohort, fasting status, and birth year

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Borena et al [13], 2011, European, CS	4,984/514,097 (mean, 44y), 12.7y	Men: Triglycerides Q5 vs. Q1 (CC) Triglycerides Q5 vs. Q1 (RC) Women: Triglycerides Q5 vs. Q1 (CC) Triglycerides Q5 vs. Q1 (RC)	1.96 (1.44-2.67) 1.26 (0.85-1.85) 1.05 (0.75-1.47) 1.33 (0.84-2.13)	Age, BMI, smoking status, and stratified by cohort, fasting status, and birth year
Van Duijnhoven et al [19], 2011, European, NC-CS	1,238/2,476 (mean, 59.0/59.1y), 5.5y	All: Triglycerides ≥ 201.9 vs. < 79.7 mg/dl (CRC) Triglycerides ≥ 201.9 vs. < 79.7 mg/dl (CC) Triglycerides ≥ 201.9 vs. < 79.7 mg/dl (RC) Total cholesterol ≥ 287.7 vs. < 211.5 mg/dl (CRC) Total cholesterol ≥ 287.7 vs. < 211.5 mg/dl (CC) Total cholesterol ≥ 287.7 vs. < 211.5 mg/dl (RC) HDL cholesterol ≥ 70.4 vs. < 43.3 mg/dl (CRC) HDL cholesterol ≥ 70.4 vs. < 43.3 mg/dl (CC) HDL cholesterol ≥ 70.4 vs. < 43.3 mg/dl (RC) LDL cholesterol ≥ 201.5 vs. < 131.9 mg/dl (CRC) LDL cholesterol ≥ 201.5 vs. < 131.9 mg/dl (CC) LDL cholesterol ≥ 201.5 vs. < 131.9 mg/dl (RC)	1.19 (0.84-1.69) 1.42 (0.91-2.31) 1.06 (0.60-1.88) 0.68 (0.50-0.92) 0.66 (0.45-0.98) 0.68 (0.41-1.13) 0.54 (0.39-0.77) 0.42 (0.28-0.65) 0.79 (0.42-1.49) 0.73 (0.54-0.99) 0.72 (0.48-1.08) 0.79 (0.48-1.29)	Age, sex, centre, follow-up time, time of blood collection, fasting status, height, weight, smoking habits, physical activity, education, consumption of fruit, vegetables, meat, fish and alcohol, intake of fibre, energy from fat and energy from non-fat

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Kitahara et al [26], 2011, Korea, CS	1314/1,189,719 (mean, 44.9y for men/49.3y for women), 12.7y	Men: Total cholesterol ≥ 240 vs. <160 mg/dl (CC) Total cholesterol ≥ 240 vs. <160 mg/dl (RC) Women: Total cholesterol ≥ 240 vs. <160 mg/dl (CC) Total cholesterol ≥ 240 vs. <160 mg/dl (RC)	1.12 (1.00-1.25) 1.06 (0.94-1.19) 1.14 (0.96-1.35) 1.13 (0.94-1.36)	Age, cigarette smoking, alcohol drinking, BMI, fasting serum glucose, hypertension, and physical activity
Inoue et al [14], 2009, Japan, CS	312/27,724 (40-69y), 10.2y	Men: Triglycerides ≥ 150 vs. <150 mg/dl (CC) Triglycerides ≥ 150 vs. <150 mg/dl (RC) HDL cholesterol ≥ 40 vs. <40 mg/dl (CC) HDL cholesterol ≥ 40 vs. <40 mg/dl (RC) Women: Triglycerides ≥ 150 vs. <150 mg/dl (CC) Triglycerides ≥ 150 vs. <150 mg/dl (RC) HDL cholesterol ≥ 50 vs. <50 mg/dl (CC) HDL cholesterol ≥ 50 vs. <50 mg/dl (RC)	1.71 (1.11-2.62) 0.54 (0.26-1.11) 1.15 (0.65-2.03) 0.41 (0.14-1.16) 1.00 (0.63-1.60) 0.52 (0.24-1.13) 1.12 (0.74-1.71) 1.14 (0.63-2.06)	Age, study area, smoking status, weekly ethanol intake, and total serum cholesterol

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
	(age), duration of follow up			
Iso et al [38]*, 2009, Japan, CS	320/33,368 (40-69y), 12.4y	Men: Total cholesterol ≥ 240 vs. <160 mg/dl (CRC) Total cholesterol ≥ 240 vs. <160 mg/dl (CC) Total cholesterol ≥ 240 vs. <160 mg/dl (RC) Women: Total cholesterol ≥ 240 vs. <160 mg/dl (CRC) Total cholesterol ≥ 240 vs. <160 mg/dl (CC) Total cholesterol ≥ 240 vs. <160 mg/dl (RC)	1.10 (0.67-1.80) 1.21 (0.68-2.14) 0.90 (0.36-2.27) 1.64 (0.89-3.05) 1.83 (0.85-3.93) 1.36 (0.49-3.79)	Age, BMI, pack year of smoking, ethanol intake, hypertension, diabetes, hyperlipidemia medication use, total vegetable intake, coffee intake and public health center
Ahn et al [28], 2009, Finland, CS	507/29,093 (50-69y), 18y	Men: Total cholesterol >276.7 vs. <203.9 mg/dl (CRC) HDL cholesterol >55.3 vs. <36.2 mg/dl (CRC)	0.86 (0.65-1.13) 1.01 (0.76-1.35)	Age, intervention, level of education, systolic blood pressure, BMI, physical activity, duration of smoking, number of cigarettes smoked per day, saturates fat intake, polyunsaturated fat intake, total calorie, alcohol consumption, and serum total and HDL cholesterol for each other
Ahmed et al [20]*, 2006, USA, CS	194/14,109 (45-64y), 11.5y	All: Triglycerides ≥ 150 vs. <150 mg/dl (CRC) HDL cholesterol High vs. Low (CRC)	1.08 (0.8-1.5) 0.84 (0.63-1.12)	Age, gender, family history of colorectal cancer, physical activity, non-steroidal anti-inflammatory drug use, NSAID use, aspirin use, pack-years of cigarette use, and grams of alcohol per week. Also adjusted for hormone-replacement therapy in women

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject (age), duration of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
Tsushima et al [21], 2005, USA, CS	504/7619 (45-65y), 31y	Men: Triglycerides Q4 vs. Q1 (CRC) Triglycerides Q4 vs. Q1 (CC) Triglycerides Q4 vs. Q1 (RC)	1.01 (0.77-1.33) 0.92 (0.67-1.26) 1.28 (0.75-2.18)	Age, elapsed time since last caloric intake, elapsed time since 50-g glucose load, BMI, heart rate, cigarette smoking history, alcohol intake, and 24-hr intake of total calories
Saydah et al [22], 2003, USA, NC-CS	173/519 (≥ 18 y), 12y	All: Triglycerides Q4 vs. Q1 (CRC)	0.69 (0.41-1.16)	Age, sex, race, time since last meal, and date of blood draw
Schoen et al [23], 1999, USA, CS	102/5849 (≥ 65 y), 6.4y	All: Triglycerides Q4 vs. Q1 (CRC) HDL cholesterol Q4 vs. Q1 (CRC) LDL cholesterol Q4 vs. Q1 (CRC)	1.4 (0.8-2.5) 0.6 (0.3-1.2) 0.5 (0.3-0.9)	Age, sex, and physical activity
Tulinius et al [15]**, 1997, Iceland, CS	338/22,946 (mean, 50.4y), 27y	Men: Triglycerides T3 vs. T1 (CRC) Total cholesterol T3 vs. T1 (CRC) Women: Triglycerides T3 vs. T1 (CRC) Total cholesterol T3 vs. T1 (CRC)	1.39 (1.13-1.71) 1.32 (1.07-1.62) 1.35 (1.06-1.72) 1.33 (1.05-1.70)	Age

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject of follow up	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors	
Gaard et al [29], 1997, Norway, CS	338/62,173 (20-49y), 14y	Men: HDL cholesterol ≥ 1.66 vs. ≤ 1.19 mmol/L (CC) HDL cholesterol ≥ 1.66 vs. ≤ 1.19 mmol/L (RC) LDL cholesterol ≥ 4.65 vs. ≤ 3.17 mmol/L (CC) LDL cholesterol ≥ 4.65 vs. ≤ 3.17 mmol/L (RC) Women: HDL cholesterol ≥ 1.66 vs. ≤ 1.19 mmol/L (CC) HDL cholesterol ≥ 1.66 vs. ≤ 1.19 mmol/L (RC) LDL cholesterol ≥ 4.65 vs. ≤ 3.17 mmol/L (CC) LDL cholesterol ≥ 4.65 vs. ≤ 3.17 mmol/L (RC)		0.99 (0.58-1.68) 0.87 (0.41-1.86) 0.99 (0.56-1.74) 1.17 (0.52-2.64) 1.23 (0.61-2.45) 0.73 (0.35-1.53) 0.57 (0.32-1.02) 1.97 (0.78-4.97)	Age and attained age, BMI, height, smoking status, and menopausal status
Chyou et al [34], 1996, USA, CS	453/7945 (45-65y), 28y	Men: Total cholesterol ≥ 240 vs. <200 mg/dl (CC) Total cholesterol ≥ 240 vs. <200 mg/dl (RC)		0.74 (0.56-0.97) 1.10 (0.68-1.79)	Age
Schatzkin et al [35]*, 1988, USA, CS	130/12,488 (25-74y), 10y	Men: Total cholesterol ≥ 246 vs. ≤ 189 mg/dl (CRC) Women: Total cholesterol >252 vs. <186 mg/dl (CRC)		0.59 (0.27-1.27) 1.00 (0.33-3.00)	Age, education, BMI, smoking, alcohol, fat as a percentage of calories, dietary fiber, age at first birth (women), age at menarche (women), parity (women), and cholesterol

(Continued)

Supplementary Table S2 (Continued)

First author, publication year (reference), Country, Type	Cases/subject	Exposure categories	RR/HR (95%CI)	Matched/Adjusted potential factors
		of follow up		
Tornberg et al [27], 1986, Sweden, CS	839/92,898 (≤75y), 16y	Men: Total cholesterol ≥ 276 vs. ≤ 224 mg/dl (CC) Total cholesterol ≥ 276 vs. ≤ 224 mg/dl (RC) Women: Total cholesterol ≥ 276 vs. ≤ 224 mg/dl (CC) Total cholesterol ≥ 276 vs. ≤ 224 mg/dl (RC)	Age 1.17 (0.81-1.68) 1.65 (1.05-2.57) 1.23 (0.84-1.81) 1.23 (0.64-2.34)	
Sidney et al [36], 1986, USA, NC-CS	245/1,470 (mean, 64.6y), 14y	All: Total cholesterol Q4 vs. Q1 (CRC)	1.2 (0.8 -1.8)	Age, sex, race, and multiphasic checkup at the same facility

BMI: body mass index; CC: colon cancer; C-CS: case-control study; CI: confidence interval; CRC: colorectal cancer; CS: cohort study; HDL: high density lipoprotein; HR: hazards ratio; LDL: low density lipoprotein; NC-CS: nested case-control study; N/A: not available; RC: rectal cancer; RR: relative risk.

* Recalculate the RR by the method proposed by Hamling et al.

** Recalculate the RR by the method proposed by Xu et al.

Supplementary Table S3. Study quality scores of prospective studies included in the meta-analysis

First author, publication year [reference]	Representativeness of the exposed cohort	Selection of the unexposed cohort	Ascertainment of exposure	Outcome of interest not present at start of study	Control for important factor or additional factor*	Assessment of outcome	Follow-up long enough for outcomes to occur**	Adequacy of follow-up of cohorts***	Total quality scores
Li [16], 2019	★	★	★	★	★	★	★	★	9
Katzke [17], 2017	★	★	★	★	★★	★	★	★	9
Chandler [11], 2016	★	★	★	★	★★	★	★	★	9
Muka [24], 2016	★	★	★	★	★★	★	★	★	9
Lu [12], 2015	★	★	★	★	★★	★	★	★	9
Agnoli [18], 2014	★	★	★	★	★★	★	★	★	9
Shin [25], 2014	★	★	★	★	★	★	★	—	8
Strohmaier [37], 2013	★	★	★	★	★★	★	★	★	9
Van Duijnhoven [19], 2011	★	★	★	★	★★	★	—	★	8
Borena [13], 2011	★	★	★	★	★★	★	★	★	9
Kitahara [26], 2011	★	★	—	★	★★	★	★	★	8
Inoue [14], 2009	★	★	★	★	★	★	★	★	8
Iso [38], 2009	★	★	★	★	★★	★	★	★	9
Ahn [28], 2009	★	★	★	★	★★	★	★	★	9
Ahmed [20], 2006	★	★	★	★	★	★	★	★	8
Tsushima [21], 2005	★	★	★	★	★★	★	★	★	9
Saydah [22], 2003	★	★	★	★	—	★	★	★	7
Schoen [23], 1999	★	★	★	★	—	★	—	★	6
Tulinius [15], 1997	★	★	—	★	—	★	★	—	5
Gaard [29], 1997	★	★	★	★	★★	★	★	★	9

Chyou [34], 1996	★	★	★	★	—	★	★	★	7
Schatzkin [35], 1988	★	★	★	★	★★	★	★	★	9
Tornberg [27], 1986	★	★	★	★	—	★	★	—	6
Sidney [36], 1986	★	★	★	★	★	★	★	★	8

* Studies that controlled for body mass index received one star, whereas studies that controlled for other important confounders such as cigarette smoking, alcohol drinking, received an additional star.

** The study with a follow-up time >10 y was assigned one star.

*** The study with a follow-up rate >75% was assigned one star.

Supplementary Table S4. Subgroup analysis of the correlation between total cholesterol concentrations and colorectal cancer risk

	No. of studies	Summary RR (95% CIs)	I^2 Value (%)	P_h^*	P_h^{**}
Overall					
Colorectal cancer	15	1.15 (1.08-1.22)	36.8	0.017	
Colon cancer	7	1.08 (0.98-1.19)	44.1	0.057	
Rectal cancer	7	1.15 (1.05-1.26)	19.4	0.259	
Subgroup analyses					
Study quality					0.679
Medium	3	1.18 (0.99-1.41)	54.7	0.031	
High	12	1.14 (1.06-1.21)	31.3	0.062	
Number of cases					0.805
< 338	7	1.32 (1.14-1.52)	0	0.532	
≥ 338	8	1.11 (1.04-1.20)	46.6	0.010	
Follow-up years					0.416
< 13	6	1.12 (1.05-1.19)	20.0	0.206	
≥ 13	9	1.22 (1.07-1.40)	51.2	0.012	
Geographic location					0.143
North America	4	0.96 (0.76-1.21)	33.5	0.185	
Europe	8	1.20 (1.06-1.36)	49.7	0.011	
Asia	3	1.14 (1.08-1.20)	0	0.717	
Gender					0.107
Male	9	1.10 (0.99-1.23)	49.2	0.016	
Female	8	1.22 (1.11-1.34)	0	0.962	
Adjustment for confounders					
Body mass index					0.553
Yes	10	1.13 (1.04-1.22)	32.5	0.064	
No	5	1.18 (1.06-1.31)	45.0	0.052	
Alcohol drinking					0.196
Yes	9	1.11 (1.01-1.23)	40.3	0.033	
No	6	1.18 (1.09-1.28)	28.2	0.147	
Cigarette smoking					0.553
Yes	10	1.13 (1.04-1.22)	32.5	0.064	
No	5	1.18 (1.06-1.31)	45.0	0.052	
Physical activity					0.304
Yes	7	1.10 (0.98-1.23)	57.0	0.008	
No	8	1.18 (1.10-1.27)	13.8	0.273	
Dietary factors					0.634
Yes	8	1.13 (0.94-1.37)	51.8	0.008	
No	7	1.15 (1.09-1.21)	19.2	0.220	
Two aforementioned confounders					0.553
Yes	10	1.13 (1.04-1.22)	32.5	0.064	
No	5	1.18 (1.06-1.31)	45.0	0.052	
Three aforementioned confounders					0.348
Yes	9	1.11 (1.01-1.23)	40.3	0.033	
No	6	1.18 (1.09-1.28)	28.2	0.147	

CI: confidence interval; N/A: not available; RR: relative risk;

* P value for heterogeneity within each subgroup.** P value for heterogeneity between subgroups with meta-regression analysis.

Supplementary Table S5. Subgroup analysis of the correlation between high-density lipoprotein cholesterol concentrations and colorectal cancer risk

	No. of studies	Summary RR (95% CIs)	I^2 Value (%)	P_h^*	P_h^{**}
Overall					
Colorectal cancer	11	0.86 (0.77-0.97)	28.8	0.117	
Colon cancer	3	0.85 (0.55-1.30)	70.8	0.008	
Rectal cancer	3	0.89 (0.65-1.22)	0	0.409	
Subgroup analyses					
Study quality					0.351
Medium	1	0.60 (0.30-1.20)	N/A	N/A	
High	10	0.87 (0.77-0.98)	29.1	0.120	
Number of cases					0.770
< 338	6	0.88 (0.75-1.04)	9.3	0.357	
≥ 338	5	0.84 (0.70-1.01)	47.7	0.054	
Follow-up years					0.273
< 13	5	0.79 (0.62-1.01)	52.2	0.033	
≥ 13	6	0.93 (0.85-1.01)	0	0.763	
Geographic location					0.421
North America	3	0.75 (0.60-0.94)	0	0.447	
Europe	6	0.87 (0.73-1.02)	38.9	0.090	
Asia	2	0.96 (0.75-1.23)	9.6	0.351	
Gender					0.476
Male	4	0.98 (0.80-1.21)	0	0.543	
Female	4	0.88 (0.71-1.09)	0	0.478	
Adjustment for confounders					
Body mass index					0.701
Yes	7	0.84 (0.71-0.99)	42.1	0.061	
No	4	0.89 (0.74-1.07)	4.6	0.392	
Alcohol drinking					0.196
Yes	9	0.86 (0.74-0.98)	42.9	0.045	
No	2	0.88 (0.65-1.18)	0	0.645	
Cigarette smoking					0.351
Yes	10	0.87 (0.77-0.98)	29.1	0.120	
No	1	0.60 (0.30-1.20)	N/A	N/A	
Physical activity					0.249
Yes	8	0.80 (0.68-0.96)	53.0	0.024	
No	3	0.96 (0.80-1.16)	0	0.700	
Dietary factors					0.242
Yes	5	0.77 (0.58-1.02)	60.6	0.019	
No	5	0.92 (0.85-1.00)	0	0.747	
Two aforementioned confounders					0.351
Yes	10	0.87 (0.77-0.98)	29.1	0.120	
No	1	0.60 (0.30-1.20)	N/A	N/A	
Three aforementioned confounders					0.409
Yes	7	0.82 (0.69-0.97)	55.4	0.022	
No	4	0.93 (0.78-1.12)	0	0.619	

CI: confidence interval; N/A: not available; RR: relative risk;


* P value for heterogeneity within each subgroup.** P value for heterogeneity between subgroups with meta-regression analysis.

Supplementary Table S6. Subgroup analysis of the correlation between low-density lipoprotein cholesterol concentrations and colorectal cancer risk

	No. of studies	Summary RR (95% CIs)	I^2 Value (%)	P_h^*	P_h^{**}
Overall					
Colorectal cancer	5	1.03 (0.75-1.41)	69.4	0.001	
Colon cancer	2	0.85 (0.62-1.15)	0	0.469	
Rectal cancer	2	0.87 (0.49-1.55)	59.6	0.084	
Subgroup analyses					
Study quality					N/A
Medium	1	0.50 (0.29-0.87)	N/A	N/A	
High	4	1.11 (0.81-1.53)	65.3	0.003	
Number of cases					N/A
< 338	3	1.26 (0.67-2.40)	83.6	0.000	
≥ 338	2	0.84 (0.64-1.11)	23.4	0.258	
Follow-up years					0.062
< 13	2	0.68 (0.52-0.89)	0	0.442	
≥ 13	3	1.28 (0.88-1.87)	63.3	0.012	
Geographic location					N/A
North America	2	0.77 (0.35-1.73)	82.6	0.017	
Europe	3	1.12 (0.77-1.63)	69.4	0.002	
Asia	0	N/A	N/A	N/A	
Gender					N/A
Male	2	1.17 (0.47-2.87)	85.3	0.001	
Female	3	1.33 (1.01-1.76)	0	0.566	
Adjustment for confounders					
Body mass index					N/A
Yes	4	1.11 (0.81-1.53)	65.3	0.003	
No	1	0.50 (0.29-0.87)	N/A	N/A	
Alcohol drinking					N/A
Yes	3	1.20 (0.78-1.87)	76.1	0.002	
No	2	0.84 (0.54-1.32)	56.2	0.058	
Cigarette smoking					N/A
Yes	4	1.11 (0.81-1.53)	65.3	0.003	
No	1	0.50 (0.29-0.87)	N/A	N/A	
Physical activity					N/A
Yes	4	1.05 (0.68-1.62)	78.9	0.000	
No	1	0.98 (0.61-1.58)	N/A	N/A	
Dietary factors					N/A
Yes	3	1.20 (0.78-1.87)	76.1	0.002	
No	2	0.84 (0.54-1.32)	56.2	0.058	
Two aforementioned confounders					N/A
Yes	4	1.11 (0.81-1.53)	65.3	0.003	
No	1	0.50 (0.29-0.87)	N/A	N/A	
Three aforementioned confounders					N/A
Yes	3	1.20 (0.78-1.87)	76.1	0.002	
No	2	0.84 (0.54-1.32)	56.2	0.058	

CI: confidence interval; N/A: not available; RR: relative risk;

* P value for heterogeneity within each subgroup.** P value for heterogeneity between subgroups with meta-regression analysis.



Supplementary Figure 1 Forest plots on the association between low-density lipoprotein cholesterol concentrations and colorectal cancer risk